An innovative Biotech company About Us
First-in-class disease-modifying products Discover our science
Therapies for neurodegenerative & traumatic disorders Our Pipeline

Our vocation is to develop first-in-class innovative drugs to treat patients with degenerative or traumatic neurological disorders
with high unmet medical needs.

Our ambition is to improve the recovery of the functionality and the quality of life of patients.

Our Discovery

During embryogenesis, a small organ named Subcommisural Organ (SCO) located in the dorsal roof of the brain differentiates and secrets the SCO-spondin, a large multi-domain protein widely distributed in the CNS and with potent activity during neurogenesis.

Learn more

Our Products

Our products are first-in-class multi-target patented peptides with high potential in many CNS disorders, as demonstrated via distinctive and multifunctional mechanism of action on neural cells.

Learn more

Diseases focus

Neurological disorders are diseases of the central and peripheral nervous system. These disorders are of major clinical problems with high unmet medical needs and currently no satisfactory treatment.

Learn more

News

INTS 2022

Dr. Sighild Lemarchant, Axoltis Pharma – Head of Preclinical R&D, will participate to the 15th International Neurotrauma Symposium meeting 2022 organized by the INTS, which will take place in Berlin, Germany, on July 17-20, 2022. A preclinical proof of concept study showing that Axoltis’ peptide NX210c, which is now at … Read more

FENS 2022

Axoltis Pharma’s R&D Team, will attend FENS Forum 2022, the Europe’s largest international neuroscience conference, which will take place in … Read more

ENCALS 2022

Dr. Sighild Lemarchant, Axoltis Pharma – Head of Preclinical R&D, will participate to ENCALS meeting 2022, the Annual Meeting of … Read more